NCT01889420 - Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

July 31, 2015

Conditions

Multiple Myeloma in Relapse

Interventions

DRUG

Combination therapy

"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~1. Everolimus daily for 28 days of a 28 day cycle;~2. Pomalidomide daily for 21 days of a 28 day cycle~3. Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."

Trial Locations (1)

87131

UNM Cancer Research and Treatment Center, Albuquerque